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Ivermectin Inhibits Molting of Wuchereria bancrofti
ThirdStage Larvae In Vitro
J. Kevin Baird*, Wiwiek Riberu, Sofyan Masbar, and Purnomo, U.S. Naval Medical Research Unit #2, Jakarta
Detachment, APO San Francisco 96356-5000. *Present address: Department of Tropical Medicine, School of Public
Health and Tropical Medicine, Tulane UniversityMedical Center, 1501 Canal Street, New Orleans, Louisiana70112

ABSTRACTr: The effectof ivermectinor diethylcarbam-

azine (DEC)on Wuchereriabancroftimoltingfromthe
thirdto the fourthlarvalstage(L3to L4)was evaluated
in vitro. L3 larvae were harvested from laboratoryrearedAedes togoi 2 wk after feedingupon a microfilaremichuman volunteer.The larvaewere kept in an
artificialmedium (Franke'sNI medium)with 10%human serum under an atmosphereof 5% CO2 for 20
days. Experimentaltubes also contained ivermectin
(0.1-1,000 ng/ml) or DEC (0.1-10,000 ng/ml). An estimated concentrationof 50 ng/ml ivermectin inhibited moltingin 50%of the larvaeexpectedto molt. For
DEC, this value was roughly 1,000 ng/ml. In this in
vitro culturesystem, ivermectininhibitedthe L3to L4
molt of W. bancroftiand was roughly 20-fold more
potent in this activity than DEC.

Humans suffering infection of the dermis and
conjunctiva by microfilariae of Onchocerca volvulus have enjoyed marked therapeutic advantages with ivermectin versus diethylcarbamazine
(DEC). Although ivermectin and DEC both
greatly diminish numbers of viable microfilariae,
ivermectin appears much less likely to elicit the
potentially maiming and life-threatening Mazzotti reaction that occasionally marks therapy
with DEC. Ivermectin shares with DEC chemoprophylactic activity against Dirofilaria immitis in dogs (McCall et al., 1984) and against
Onchocerca lienalis in vitro, i.e., inhibition of L3
molting (Court et al., 1985; Lok et al., 1987).
However, Taylor et al. (1988) found that ivermectin failed to prevent infection of chimpanzees by 0. volvulus. In view of a possible chemoprophylactic role for ivermectin against
bancroftian filariasis in humans, we evaluted the
effects of ivermectin on the molting of L3 larvae
of Wuchereria bancrofti in vitro.
Third stage larvae of W. bancrofti were harvested from laboratory-rearedAedes togoi 14 days
after feeding upon a microfilaremic human volunteer living in Jakarta, Indonesia. The larvae
were harvested and cultured as described by
Franke et al. (1987), except that ivermectin or

DEC was added to the culture medium (Frank's
NI medium with 10% human serum). The drugs
were present in the culture medium through the
duration of the experiments. Negative controls
consisted of at least 2 tubes of 20-25 larvae per
tube cultured in medium lacking drugs. These
controls were run with each experiment in which
effects of drugs were evaluated. Tubes for evaluation of effects of drugs also contained 20-25
larvae, and for each determination the duplicate
sets of tubes were run on at least 2 occasions.
Experiments were terminated after 20 days, soon
after most control larvae had molted. The percent molt among drug-treated larvae was calculated using the following equation, where T
denotes test condition (i.e., drug present) and C
denotes negative control: % molt = {L4T - [(L4C
- (L4C + L3C))(L3T + L4T)]} -100.
Inclusion of the proportion of negative control
larvae molting in the denominator of the % molt
calculation eliminated effects of drug-independent inhibition of molt. In all experiments, this
proportion ranged between 0.75 and 1.0, i.e., the
proportion of larvae expected to molt in the absence of drug effects. Most L3 larvae in either test
or control tubes were living when the experiment
was terminated. Mortality specifically attributable to drugs was not documented.
Figure 1 illustrates the dose-dependent inhibition of molting by ivermectin or DEC. Neither
drug caused appreciable inhibition below 10 ng/
ml. The estimated dose for inhibiting molt among
half the larvae was 50 ng/ml for ivermectin, and
1,000 ng/ml for DEC. As much as 500 ng/ml
ivermectin was required to inhibit molt completely, and this occurred only at the highest concentration of DEC (10,000 ng/ml).
Just what the results in Figure 1 mean in terms
of how the drugs may act in humans is uncertain.
There are several distinct concerns in this regard,
foremost among them are questions regarding
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FIGURE 1. Molting of the third stage larva (L3) of
Wuchereria bancrofti in vitro in the presence of increasing concentrations of ivermectin or diethylcarbamazine (DEC). Each point is the mean of at least 2
replicates measured on 2 occasions. The line drawn for
each drug is a best-fit curve.

activity of metabolites of ivermectin versus parent. Fink and Porras (1989) found that appreciable proportions of ivermectin were metabolized rapidly (<5 hr) and that after a single
therapeutic dose, metabolites persisted at about
50 ng/ml human plasma for at least 3 days whereas less than 5 ng parent ivermectin remained per
ml plasma after just 24 hr. From the pharmokinetic point of view, hope for chemoprophylactic activity of ivermectin lies in its longer lived
metabolites. Another concern is the possibility
of sequestration of ivermectin in glass and plastics as reported by Rew et al. (1986). Unless the
concentration of drug in the final incubation medium actually is measured, it is not possible to
know the concentration available to act upon the
parasites.
In summary, we have shown that ivermectin
inhibits a molt of W. bancrofti that occurs in
human tissues as part of the development of this
parasite. Ivermectin was roughly 20-fold more
effective than DEC in this activity. Studies evaluating the effects of the human metabolic derivatives of ivermectin are required to evaluate the
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potential of this drug as a chemoprophylactic
agent against bancroftian filariasis.
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